

Subject Index

- Aberrant crypt foci, 7, 103, 116
Acetaldehyde, 216, 247, 248, 249, 279
N-Acetylcysteine, 261
N-Acetyltransferase, 5, 36, 142, 181, 182, 243, 276
Actinic keratoses, 7, 85, 88
Adducts, *see* DNA adducts, Protein adducts
Adenoma
 colorectal, 7, 14, 15, 18, 21, 103, 105, 113–116, 133
 hepatic, 223, 226
Adenomatous atypical hyperplasia, 192, 200, 265
Aerodigestive tract, 5, 18, 34, 37, 257, 261, 272
Aflatoxins, 5
 albumin adducts, 41, 216, 217
 DNA adducts, 32, 216, 218, 242
 and liver cancer, 216, 218–220, 223, 241
 metabolites, 31, 216
 protein adducts, 31, 217
Age, 119, 131, 132, 166
Ageing, breast tissue, 163, 166
AIDS, 21, 38, 39
Albinism, 93
Albumin adducts, 31, 41, 216–218, 249
Alcohol
 and colorectal cancer, 62, 65
 and liver cancer, 5, 216, 223, 241
 metabolism, 279
 and oral cancer, 247, 271
2-Amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine, *see* PHIP
 Δ 4-Androstenedione, 150, 151
Androgens, 5, 150, 157, 193, 199, 201–203, 208
Angiogenesis, 194
Antiestrogens, 16
Antioxidants, 4, 58, 97, 105, 191, 208, 232
 α -1-Antitrypsin deficiency, 241
APC gene, 15, 20, 22, 33, 37, 115, 117, 134–140
Apoptosis, 15, 154, 192, 194, 258
Aromatase, 151, 157, 180
Ashkenazi Jews, 140, 144, 179
Aspirin, 37
Ascorbic acid, *see* Vitamin C
Ataxia telangiectasia, 37, 180
Barrett's oesophagus, 8, 14, 20
Benzo[a]pyrene, 245, 247, 272
Betel quid, 247, 249, 272
Bias, 63–65
Biomarkers, 27
 definition, 1
 exposure, 3–6, 29–32
 intermediate effect, 6–8, 13–22
 predictive value, 50
 prognostic value, 38
 surrogacy, 38–41
 susceptibility, 8–10
 validity, 2, 5, 29, 57, 63, 70
Bile acids, 102, 105
Bladder, urinary
 cancer, 18, 20, 34, 36, 58
 precancer, 14
Bloom's syndrome, 37
Bowel, large, *see* Colorectum
Bowman–Birk inhibitor, 53
Bran, 119
Breast
 ATM gene, 180
 BRCA genes, 15, 37, 62, 178–184
 cancer, 34, 37
 and diet, 149
 and hormonal factors, 5, 149–159, 163, 166, 180
 density, 7, 163–167, 173
 ductal carcinoma *in situ*, 7, 14, 35, 171–174
 intermediate-effect biomarkers, 163–167, 171–174
 mammography, 7, 163, 173, 174
 screening, 173, 174, 182
 susceptibility biomarkers, 177–184
 tamoxifen trial, 49, 184
Broccoli, 38, 281
Calcium, 101, 105, 115, 116
Calprotectin, 104
Carbohydrates, 149
Carcinoembryonic antigen, 32, 117
Carcinoid tumours, 32
 β -Carotene, 5, 58, 105, 116, 119, 141, 259–262, 279, 280
Carotenoids, 9
Catechins, 280
Catechol-O-methyltransferase (COMT), 152–154, 180, 182
 β -Catenin, 115, 137
CD44, 118
Celecoxib, 21, 22, 37
Cervix uteri, cancer of, 3, 32, 38
Children, 87, 139
Chlorophyllin, 220
Chromosome alterations, 18, 172–173
Cigarette smoking, *see* Tobacco
Cirrhosis, 241
Clofibrate, 232
Colorectum
 aberrant crypt foci, 7, 103, 116
 adenomas, 7, 14, 15, 18, 21
 cancer, 20, 21, 36, 37, 62, 101
 and alcohol, 65
 dietary factors, 101, 105–108, 115
 DNA adducts, 104
 exposure biomarkers, 5, 101–104
 intermediate-effect biomarkers, 7, 103, 113–120
 intervention trials, 52, 105–108
 p53 mutations, 117
 susceptibility biomarkers, 131–144
 see also Hereditary non-polyposis colorectal cancer and Familial adenomatous polyposis
Confounding, 65
Contraceptives, oral, 156, 241
Cotinine, 5
Cowden syndrome, 178
COX-2, 5, 10, 16, 62
Cyclins, 18, 172
Cyclobutane pyrimidine dimers, 69
Cytochrome P450 (CYP), 5, 97, 152, 180, 242, 272–275, 277–278, 281
 CYP1A1, 97, 242, 250, 272
 CYP1A2, 65, 219, 250, 277, 281
 CYP2A6, 242, 277
 CYP1B1, 277
 CYP2B6, 242
 CYP2C9, 277
 CYP2C19, 277
 CYP2D6, 97, 250, 274
 CYP2E1, 65, 250, 274
 CYP3A2, 208
 CYP3A4, 210, 217, 277
 CYP17, 208
 CYP19, 182
Dehydroepiandrosterone, 151, 157, 228, 231–234
Detoxification, 58, 96, 142, 154, 216, 245, 249, 272, 276, 281
Diabetes, 229
Dietary factors, 58
 breast cancer, 149
 colorectal cancer, 101, 105–108, 115

- liver cancer, 216, 241
prostate cancer, 191
- 2-Difluoromethylomithine, 18, 22, 37, 51–53
- DNA
adducts, 5, 6, 8, 29, 31, 57–58, 104, 271
aflatoxin, 32, 216, 218, 242
bulky, 58, 273, 277, 278
etheno, 5, 104, 108
exocyclic, 272
postlabelling analysis, 31, 58, 104, 247
in skin, 4
tobacco carcinogens, 245, 247, 273
methylation, 34, 248, 264
repair, 8, 36, 58, 61, 70, 74, 94, 103, 133, 138, 181
synthesis, unscheduled, 8
- Ductal carcinoma *in situ*, 7, 14, 35, 171–174
- Dysplasia, 8, 113, 258, 265
- Endocrine factors, *see* Hormones
- Enzyme
antioxidant, 97
carcinogen-metabolizing, 9, 35, 58, 241, 271–282
DNA repair, 35, 37, 58, 74
induction, 272, 280, 281, 282
steroid-metabolizing, 151–154
see also Cytochrome P450, Glutathione S-transferase
- Epidermal growth factor (EGF), 16, 18
- Estradiol, 150, 151, 158
- Estrogens, 150–156, 166
- Estrogen receptor, 16, 18
- Ethanol, *see* Alcohol
- Etheno adducts, 5, 104, 108
- Ethical issues, 10, 143
- Exercise, 115, 149, 157
- Exposure biomarkers, 3, 29–32
breast, 149–159
colorectum, 5, 101–104
liver, 3, 215–220
lung, 245–251
prostate, 191
skin, 4, 69–78
validation, 5
- Faecal occult blood test, 101, 104
- Familial adenomatous polyposis, 9, 18, 20, 37, 103, 104, 116, 119, 131, 136–138, 142
- Fanconi's anaemia, 37
- Fat, 101, 115, 116, 119, 149, 191
- Fenretinide, 156, 184, 259
- α -Fetoprotein, 32
- Fibre, 101, 105, 115, 116
- Field cancerization, 257
- Finasteride, 202, 211
- Fish oil, 119
- Flavonoids, 158
- Fluorescent bronchoscopy, 265
- Foci of altered hepatocytes, 223–229, 233–235
- Folate, 115, 141
- Food, *see* Dietary factors
- Fruit, 58, 61, 107, 115, 116
- Gene
amplification, 16
APC, 15, 20, 22, 33, 37, 115, 134–140
AR, 209
ATM, 180
BRCA, 15, 37, 62, 178–184
CDKN2A, 95
COMT, 154, 180, 182
DNA repair, 35, 37, 94, 133, 138
HPRT, 33
MOM1, 131, 140
MSH2, 140, 178
MTHFR, 141
NAT2, 5, 36, 142, 181, 182, 243, 276
penetrance, 8, 10, 35, 62
PTCH, 95
PTEN, 139, 178
ras, 15, 33, 95, 115, 117, 135, 263, 265
SHH, 95
SMO, 95
SRDA5A2, 209, 211
see also Cytochrome P450, Glutathione S-transferase and p53
- Genetic polymorphism, *see* Polymorphism
- Genomic instability, 32, 34, 263
- Glucose-6-phosphate dehydrogenase, 233
- Glucuronides, 30, 153
- γ -Glutamyltranspeptidase, 228, 233
- Glutathione S-transferase (GST), 38, 218, 272, 281
GSTM1, 5, 36, 63, 96, 97, 181–183, 242, 273, 275, 280, 282
GSTM3, 275, 276
GSTP1, 96, 181–183, 228, 275, 276, 282
- GSTT1, 96, 181, 275, 276, 282
and breast cancer, 181–183
and liver cancer, 233
and lung cancer, 275–276
and skin cancer, 96, 97
- Glycogen, 226–230
- Glycophorin A assay, 33
- Gorlin's syndrome, 139
- Growth hormone-releasing hormone, 155
- Haemochromatosis, 241
- Haemoglobin adducts, 31, 249
- Head and neck cancer, 16, 18, 261
(*see also* Oral cancer)
- Hepatitis viruses, 3
and liver cancer, 5, 33, 215, 220, 223, 241
vaccination, 218
- Hepatocellular carcinoma (HCC), *see* Liver, cancer of
- Hereditary non-polyposis colorectal cancer, 9, 16, 37, 119, 131–133, 138–139, 178
- Heterocyclic amines, 5, 30, 32, 36, 65, 104, 141, 277
- Heterogeneous nuclear ribonucleoprotein (hnRNP), 7, 262
- Homocysteine, 62
- Hormones
and breast cancer, 5, 149–159, 163, 166, 180
exogenous, 149
insulin, 151, 154–158, 229
and liver cancer, 229, 232
and prostate cancer, 5, 201–203
replacement therapy, 156, 159, 166
steroids, 150–154, 157, 180
thyroid, 232, 234
- Human immunodeficiency virus, 38, 39
- Human papillomavirus, 3, 38
- 5-Hydroxyindoleacetic acid, 32
- 8-Hydroxydeoxyguanosine, 5, 61
- Iceland, 179
- Immunosuppression, 85
- Inflammatory bowel disease, 134
- Insulin, 151, 155, 156, 158, 229
- Insulin-like growth factors, 16, 150, 154–159, 208, 231
- Intermediate effect biomarkers, 6–8, 13–22, 32–35, 49
breast, 163–167, 171–174
colorectum, 7, 103, 113–120
liver, 223–235

- lung, 257–266
 prostate, 191–197, 200–203
 skin, 81–89
- Intervention studies, 16, 27
 breast, 34, 155–158, 184
 colorectum, 52, 105–108, 116
 liver, 7, 218, 220
 lung, 259–262, 266, 279
 oltipraz, 31, 38
 population selection, 3, 8, 9, 18, 27, 35, 283
 phase I, 19
 oral leukoplakia, 53
 phase II, 2, 18
 breast, 7, 19
 colon, 52
 liver, 220
 oral leukoplakia, 53
 prostate, 19
 phase III, 2, 18
 breast, 157
 colon, 53
 prostate, 19, 210–211
- Intraepithelial neoplasia, 8, 13, 15, 35
 cervical, 35
 ductal carcinoma *in situ*, 7, 14, 35
 prostate, 7, 14, 35, 191–197, 200–203
- 8-Isoprostane F-2 α , 61
- Isothiocyanates, 5, 31, 38, 248, 250, 281
- Isotretinoin, 259
- Juvenile polyposis, 139
- Kidney tumours, 34
- Knock-out mice, 10
- Labelling index, 118, 119
- Large bowel, *see* Colorectum
- Leukaemia, 37
- Leukoplakia, 53
- Li–Fraumeni syndrome, 10, 37, 95, 178
- Linoleic acid, 108
- Lipid peroxidation, 5, 104, 108, 272, 279
- Liver
 angiosarcoma, 215
 cancer of, 32, 215
 and aflatoxins, 5, 7, 33, 218, 223
 and alcohol, 5, 223
 and hepatitis viruses, 5, 33, 215, 220, 223, 241
p53 mutations, 7, 38, 218
 cholangiocarcinoma, 215
 exposure biomarkers, 3, 215–220
 hepatocellular carcinoma, 7, 41, 215, 223, 241
 intermediate effect biomarkers, 223–235
 susceptibility biomarkers, 241–243
- Lobular carcinoma *in situ*, 35, 171
- Loss of heterozygosity, 16, 258, 263
- Lung, cancer of, 34, 37
 atypical cells in sputum, 7, 259, 261
 and GST polymorphism, 63
 exposure biomarkers, 245–251
 intermediate effect biomarkers, 257–266
 non-small-cell, 34
 and oxidative stress, 272
p53 mutations, 263
 retinoic acid receptor β , 7, 258
 second primary, 261, 262
 and smoking, 245, 257
 susceptibility biomarkers, 271–283
- Luteinizing hormone, 157
- Lycopene, 191, 208
- Lymphoma, 37
- Lynch syndrome, *see* Hereditary non-polyposis colorectal cancer
- Mammography, 7, 163, 173, 174, 184
- Measurement error, 57, 61, 113, 117
- Meat, 58, 101, 104, 115, 119, 141
- Melanin, 94
- Melanoma, 7, 70, 81, 86–87, 93 (*see also* Skin, cancer)
- Menopause, 166
- Mercapturic acids, 30
- Metabolism, 9
 of chemopreventive agents, 38
 carcinogen, 35, 219, 271–282
 oxidative, 35
 steroid hormone, 151, 153, 155, 180
- Metabolites
 carcinogenic, 61
 urinary, 30–31, 216, 249
- Metaplasia, bronchial, 258, 261
- Methionine, 62
- Methylation, DNA, 34, 248, 264
- Methylenetetrahydrofolate reductase, 62, 141
- 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), 30, 245, 272, 274, 277, 282
- Microsatellites, 16, 34, 134, 138, 210, 263
- Mismatch repair, 37, 133, 134, 138
- Monooxygenase, *see* Cytochrome P450
- Muir–Torre syndrome, 178
- Mutations, 8, 32, 271
ATM gene, 180
- APC gene, 9, 22, 37, 115, 117, 135–140
 breast cancer genes, 37, 178
 β -catenin, 115
 mismatch repair genes, 37, 138
MSH2, 178
p53 gene, 10, 37
 in colorectal cancer, 115, 116, 117
 in liver cancer, 7, 33, 218, 220, 242
 in lung tumours, 263, 274
 in skin tumours, 7, 82
PTEN gene, 139, 178
ras gene, 115, 117, 135, 263
 screening, 179, 182
STK11, 178
 tyrosinase gene, 94
- NAD(P)H:quinone oxidoreductase (NQO1), 97, 278
- Naevus, 4, 7, 84, 87, 89, 95, 139
- NAT2* gene, 36, 142, 181, 182, 243, 276
- Nicotine, 31, 245, 251, 274, 277
- Nitrosamines, 32, 245, 247–250, 277
- N*-Nitrosornicotine, 272, 274, 278
- Nonsteroidal anti-inflammatory drugs, 9, 18, 21, 22, 119
- Nutrition, *see* Dietary factors
- Obesity, 115, 149, 151, 155, 157, 191
- Oesophagus, Barrett's, 8, 14, 20
- Oltipraz, 31, 38, 41, 218, 232
- Oncogene, 14, 18 (*see also specific genes*)
- Oral cancer
 leukoplakia, 53, 276
 susceptibility markers, 271–283
 and tobacco use, 247, 271
- Ornithine decarboxylase, 18, 51
- Ovary, cancer of, 178
- Overtreatment, 174
- Oxidative stress, 4, 5, 6, 8, 97, 272
- 8-Oxodeoxyguanosine, 32, 104, 248
- p53*, 18
 and breast cancer, 18
 gene mutations, 7, 10
 in colorectal cancer, 117
 Li–Fraumeni syndrome, 10, 37, 178
 in liver cancer, 7, 33, 218, 220, 242
 in lung tumours, 263, 274
 in skin tumours, 7, 82
 knock-out mice, 10

- polymorphism, 242, 243
 Papanicolaou test, 32
 Parity, 165
 Penetrance, gene, 8, 10, 35, 62
 Peroxisome proliferators, 231–234
 Peutz–Jeghers syndrome, 139, 178
 Phenobarbital, 32
 Phenyl isothiocyanate, 31, 248, 250, 281
 PHIP, 104
 Photoproducts, 32, 69
 Physical activity, *see* Exercise
 Phytoestrogens, 158
 Polycyclic aromatic hydrocarbons, 5, 32, 245, 247, 249, 272, 273
 Polycystic ovary syndrome, 150, 157
 Polymorphism, genetic, 8, 36, 271–283
 N-acetyltransferase, 5, 36, 142, 276
 APC, 139
 CYP genes, 97, 242, 272–274, 277–278
 COMT, 154
 glutathione *S*-transferase (*GST*), 36, 38, 96, 275–276
 methylene-tetrahydrofolate reductase, 62, 141
 p53, 242, 243
 SRDA5A2, 209, 211
 VDR, 210
 xenobiotic-metabolism, 36, 217, 271–282
 Polyps, *see* Adenoma
 Polyphenols, 5, 280, 282
 Postlabelling, 31, 58, 69–71, 104, 247
 Predictive value of biomarker, 50
 Progesterone, 150, 166
 Progestogens, 150
 Prognostic value of biomarker, 38
 Protactin, 167
 Proliferating cell nuclear antigen, 118
 Proliferation, 15, 16, 103, 105, 116, 135, 154, 192, 224, 232
 mucosal, 118–120, 194
 Proportionate risk, 50
 Prostate
 cancer, 191, 199
 exposure biomarkers, 5
 hormonal effects, 5, 201–203
 intraepithelial neoplasia, 7, 14, 191–197, 200–203
 -specific antigen, 18, 32, 194, 200, 203
 susceptibility biomarkers, 207–211
 Protein adducts, 29, 31, 249
 Radiation, 224, 226
 Raloxifene, 156, 184
ras gene, 15, 33, 95, 115, 117, 135, 263, 265
 Reactive oxygen species, 94, 96, 97, 272, 278
 Recommendations, 11
 Renal cancer, 34
 Replacement therapy, 156, 159, 166
 Retinoblastoma, 37, 95
 13-*cis*-Retinoic acid, 258, 261
 all-*trans*-Retinoic acid, 279
 Retinoids, 184, 258, 259, 279
 Retinyl palmitate, 261, 279
 Screening
 for breast cancer, 173, 174, 182
 familial adenomatous polyposis, 142
 mutation, 179
 for prostate cancer, 199, 201, 203
 Second primary lung cancer, 261, 262
 Selenium, 5, 105, 194, 208, 261
 Sex hormone binding globulin, 150, 151, 155, 157, 158, 208
 Skin
 cancer, 36, 37, 69, 81–82, 93–98
 (*see also* Melanoma)
 colour, 76
 exposure biomarkers, 4, 69–78
 intermediate-effect biomarkers, 7
 p53 mutations, 7, 82
 susceptibility biomarkers, 93–98
 Smoking, *see* Tobacco
 Solar radiation, 69, 81
 Somatostatin, 155
 Soybean, 53
 Sputum atypia, 7, 259, 261
 Steroids, 150–154, 157, 180
 Sulfate esters, 30, 153
 Sulindac, 22, 37, 53, 116, 119
 Sunburn, 7, 69, 82, 88, 93
 Sunscreen, 75, 82, 85, 93, 97
 Surrogacy, 38–41
 Surrogate end-point biomarkers, 13–22, 29 (*see also* Intermediate-effect biomarkers)
 Susceptibility biomarkers, 8–10, 35–38
 breast cancer, 177–184
 colorectal cancer, 131–144
 liver cancer, 241–243
 lung, 271–283
 prostate cancer, 207–211
 skin cancer, 93–98
 Tanning, 70, 75
 Tea, 234, 280
 Testosterone, 150, 157, 201
 Thymidine glycol, 32
 Thyroid, 32, 232, 234
 Tobacco smoking
 carcinogen metabolism polymorphism, 271–283
 carcinogens, 246, 272
 chewing, 272
 and lung cancer, 245, 257, 271, 274
 and oral cancer, 271
 and oxidative stress, 272
 -specific nitrosamines, 32, 245, 247–250, 272, 277
 Tocopherols, 5, 262 (*see also* Vitamin E)
 Transforming growth factor (TGF), 16, 18, 115, 134, 138
 Transgenic mice, 6, 8, 9, 226, 242
 Trials, *see* Intervention studies
 Tumour-suppressor genes, 15, 18, 37, 179, 263 (*see also specific genes*)
 Turcot's syndrome, 139
 Tyrosinase, 94
 Ulcerative colitis, 134
 Ultraviolet radiation, 36, 69, 81, 93
 cis-Urocanic acid, 86
 Vaccination, 218, 223
 Validity, 2, 5, 29, 63
 Vegetables, 9, 58, 61, 65, 107, 115, 116, 281, 282
 Vinyl chloride, 215
 Vitamins
 A, 119, 258, 261, 279
 C (ascorbic acid), 32, 105, 116, 119
 D, 180, 208, 210
 E (α -tocopherol), 58, 105, 116, 119, 194, 208, 259, 261, 280
 Watercress, 30, 250, 282
 Wnt signalling, 137
 Xenobiotic metabolism, 9, 35, 58
 Xeroderma pigmentosum, 36, 37, 70, 94
 Tamoxifen, 49, 62, 156, 159, 174, 184